OraSure technologies CFO Kenneth J. McGrath buys $201,683 in common stock

Kenneth J. McGrath, the Chief Financial Officer of OraSure Technologies Inc. (NASDAQ:OSUR), purchased a significant amount of the company’s common stock recently. According to a filing with the Securities and Exchange Commission, McGrath acquired 64,000 shares on February 27, 2025, at a weighted average price of $3.1513 per share. The purchase comes as the stock trades near its 52-week low of $2.69, having declined about 18% in the past week. This transaction, which took place on the open market, amounted to a total value of $201,683. Following this purchase, McGrath’s total direct ownership of OraSure Technologies stock increased to 371,013 shares. The shares were acquired at prices ranging from $3.08 to $3.275. According to InvestingPro analysis, OraSure maintains a strong financial position with more cash than debt, and analysts expect the company to return to profitability this year. The stock currently appears undervalued based on InvestingPro’s Fair Value model, with 10+ additional exclusive insights available to subscribers.

In other recent news, OraSure Technologies reported its fourth-quarter 2024 earnings, revealing revenue figures that surpassed expectations. The company recorded a total revenue of $37.45 million, exceeding the forecast of $36.72 million. Despite this revenue beat, the company’s gross margin fell short of consensus expectations, reported at 40.1% instead of the anticipated 43.4%. This discrepancy was attributed to reduced COVID-19 testing revenue and a shift in international sales mix. Looking forward, OraSure has provided guidance for the first quarter of 2025, projecting revenues between $27.5 million and $31.5 million.

Citi analyst Patrick Donnelly responded to these developments by lowering OraSure’s stock price target from $9 to $6, while maintaining a Buy rating. This adjustment reflects concerns over future profitability and uncertainties in U.S. funding, which are impacting OraSure’s revenue guidance. Additionally, OraSure’s strategic acquisitions, including Sherlock Biosciences, and product innovations are expected to contribute to future growth. The company also ended the quarter with a strong cash position of $268 million, with plans to expand its gross margin towards 50% by 2025.

Despite these positive aspects, investor sentiment appeared cautious, as reflected in the stock’s decline following the earnings release. OraSure’s management continues to monitor potential impacts from changes in international government-funded markets and academic research funding, which could affect future revenue. The company remains focused on operational efficiencies and expanding its molecular diagnostics platform, aiming to drive long-term growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.